Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.
Novo Nordisk A/S (NYSE: NVO) continues to bolster its obesity portfolio. In the latest move, the Danish pharma giant has acquired Embark Biotech.